Indian patient groups say they are also contemplating following the example set by Initiative for Medicines, Access & Knowledge (I-MAK), which announced its filing in the Mumbai Patent Office, on Thursday. Meanwhile, Indian generic drug maker Cipla Ltd claims it, too, might fight the Abbott patent filing.